GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Pressure BioSciences Inc (OTCPK:PBIO) » Definitions » Cash Flow from Investing

Pressure BioSciences (Pressure BioSciences) Cash Flow from Investing : $-0.01 Mil (TTM As of Sep. 2023)


View and export this data going back to 1996. Start your Free Trial

What is Pressure BioSciences Cash Flow from Investing?

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

For the three months ended in Sep. 2023, Pressure BioSciences spent $0.00 Mil on purchasing property, plant, equipment. It gained $0.00 Mil from selling property, plant, and equipment. It spent $0.00 Mil on purchasing business. It gained $0.00 Mil from selling business. It spent $0.00 Mil on purchasing investments. It gained $0.00 Mil from selling investments. It paid $0.00Mil for net Intangibles purchase and sale. And it paid $0.00 Mil for other investing activities. In all, Pressure BioSciences spent $0.00 Mil on investment activities in financial market and operating subsidiaries for the three months ended in Sep. 2023.


Pressure BioSciences Cash Flow from Investing Historical Data

The historical data trend for Pressure BioSciences's Cash Flow from Investing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pressure BioSciences Cash Flow from Investing Chart

Pressure BioSciences Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Cash Flow from Investing
Get a 7-Day Free Trial Premium Member Only Premium Member Only - -0.02 -0.80 -0.12 -0.02

Pressure BioSciences Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Cash Flow from Investing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.02 - - - -

Pressure BioSciences Cash Flow from Investing Calculation

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

If a company spends cash on property, plant and equipment (PPE), this will reduce their cash position. This is called Capital Expenditures (CPEX).

Likewise, if a company buys another company for cash, this will reduce their cash position.

Pressure BioSciences's Cash Flow from Investing for the fiscal year that ended in Dec. 2022 is calculated as:

Pressure BioSciences's Cash Flow from Investing for the quarter that ended in Sep. 2023 is calculated as:


Cash Flow from Investing for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.01 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Pressure BioSciences  (OTCPK:PBIO) Cash Flow from Investing Explanation

Cash flow from investing contains nine items:

1. Purchase Of Property, Plant, Equipment:
Purchase of PPE indicates the amount used to purchase property, plant, and equipment.

Pressure BioSciences's purchase of property, plant, equipment for the three months ended in Sep. 2023 was $-0.00 Mil. It means Pressure BioSciences spent $0.00 Mil on purchasing property, plant, equipment.

In the capital spending for property, plant and equipment (PPE), some part of spending may be from the expansion of business. The business needs more property, plant and equipment (PPE) as it grows. Another part may be from replacement of the property, plant and equipment (PPE) of existing business. For some companies, the cash spent on replacing of the property, plant and equipment (PPE) of the existing business will be close to the depreciation of property, plant and equipment (PPE) reported in the income statement.

In Warren Buffett's definition of Owner's Earnings, he deducts the estimate of the cost of replacing the property, plant and equipment (PPE) of the existing business from cash flow from operations. The cash spent on the new property, plant, and equipment is not deducted. The reason is because these are not costs of the existing business. In his 1986 letter to shareholders, Warren Buffett wrote this about owner earnings:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume....Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

2. Sale Of Property, Plant, Equipment:
Sale of PPE indicates the amount gained from selling property, plant, and equipment.

Pressure BioSciences's sale of property, plant, equipment for the three months ended in Sep. 2023 was $0.00 Mil. It means Pressure BioSciences gained $0.00 Mil from selling property, plant, and equipment.

3.Purchase Of Business:
Purchase of business indicates the amount used to purchase business.

Pressure BioSciences's purchase of business for the three months ended in Sep. 2023 was $0.00 Mil. It means Pressure BioSciences spent $0.00 Mil on purchasing business.

4. Sale Of Business:
Sale of business indicates the amount gained from selling business.

Pressure BioSciences's sale of business for the three months ended in Sep. 2023 was $0.00 Mil. It means Pressure BioSciences gained $0.00 Mil from selling business.

5. Purchase Of Investment:
Purchase of Investments represents cash outflow on the purchase of investments in securities.

Pressure BioSciences's purchase of investment for the three months ended in Sep. 2023 was $0.00 Mil. It means Pressure BioSciences spent {stock_data.stock.currency_symbol}}0.00 Mil on purchasing investments.

6. Sale Of Investment:
Sale of Investments represents cash inflow on the sale of investments in securities.

Pressure BioSciences's sale of investment for the three months ended in Sep. 2023 was $0.00 Mil. It means Pressure BioSciences gained $0.00 Mil from selling investments.

7. Net Intangibles Purchase And Sale:
Net Intangibles purchase and sale means the net cash inflow received by a company that comes from the purchase and sale of intangibles. It equals the cash received from sale of intangibles minus the cash spent on purchasing intangibles.

Pressure BioSciences's net Intangibles purchase and sale for the three months ended in Sep. 2023 was $0.00 Mil. It means Pressure BioSciences paid $0.00 Mil for net Intangibles purchase and sale.

8. Cash From Discontinued Investing Activities:
Cash from discontinued investing activities means the cash received by a company that comes from the discontinued investing activities.

Pressure BioSciences's cash from discontinued investing activities for the three months ended in Sep. 2023 was 0.00 Mil. It means Pressure BioSciences paid $0.00 Mil for discontinued investing activities.

9. Cash From Other Investing Activities:
Cash from other investing activities means the cash received by a company that comes from other investing activities.

Pressure BioSciences's cash from other investing activities for the three months ended in Sep. 2023 was $0.00 Mil. It means Pressure BioSciences paid $0.00 Mil for other investing activities.


Pressure BioSciences Cash Flow from Investing Related Terms

Thank you for viewing the detailed overview of Pressure BioSciences's Cash Flow from Investing provided by GuruFocus.com. Please click on the following links to see related term pages.


Pressure BioSciences (Pressure BioSciences) Business Description

Traded in Other Exchanges
N/A
Address
14 Norfolk Avenue, South Easton, MA, USA, 02375
Pressure BioSciences Inc is engaged in the healthcare division. The firm is a leader in the development & sale of innovative, enabling, pressure-based platform solutions for the worldwide life sciences industry. The company has developed and patented a technology platform that can control the sample preparation process. This process, called pressure cycling technology (PCT), uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels. The company is also the distributor of the Constant Systems (CS) cell disruption equipment, parts, and consumables. Its products include Barocyclers, External Pressure Calibration Device Kits, MicroTubes, HUB High-Pressure Generators, and Accessories.
Executives
Daniel Joseph Shea officer: Senior Vice President & CFO 2 MINUTEMAN ROAD, MEDFIELD MA 02052
Bradford Addison Young officer: Chief Commercial Officer 513 LITTLE JOHN HILL, ANNAPOLIS MD 21405
Richard T Schumacher director, officer: Chief Executive Officer 375 WEST STREET, WEST BRIDGEWATER MA 02379
Nathan Lawrence other: VP Sales and Marketing 321 MANLEY STREET, WEST BRIDGEWATER MA 02379
Richard Thomley officer: Chief Financial Officer C/O PRESSURE BIOSCIENCES, INC., 14 NORFOLK AVE., SOUTH EASTON MA 02375
Kevin Pollack director 150 RAINVILLE ROAD, TARPON SPRINGS FL 34689
Michael S Urdea director 100 BUNCE MEADOWS DRIVE, ALAMO CA 94507
Alexander V Lazarev officer: VP of REsearch and Development 18 WINCHESTER DRIVE, LEXINGTON MA 02420
Edmund Y Ting officer: Senior VP of Engineering 23642 123RD PLACE SOUTHEAST, KENT WA 48031
Vito J Mangiardi director 12 POINT GALLINAS ROAD, SAN RAFAEL CA 94903
Jeffrey N Peterson director 1031 SHORELINE DRIVE, SAN MATEO CA 94404
Mir Conrad F officer: CFO 19 BRIER LANE, CLIFTON NJ 07012
Clayton A Struve 10 percent owner 175 W JACKSON BLVD, SUITE 440, CHICAGO IL 60604
Css Llc/il other: (a) 175 WEST JACKSON BLVD, SUITE 440, CHICAGO IL 60604
R Wayne Fritzsche director 835 GREENS PARKWAY, SUITE 150, HOUSTON TX 77067

Pressure BioSciences (Pressure BioSciences) Headlines

From GuruFocus